Mostrar el registro sencillo del ítem

dc.contributor.author
Nocera, David Andres  
dc.contributor.author
Roselli, Emiliano  
dc.contributor.author
Araya, Paula  
dc.contributor.author
Nuñez, Nicolas Gonzalo  
dc.contributor.author
Lienenklaus, Stefan  
dc.contributor.author
Jablonska, Jadwiga  
dc.contributor.author
Weiss, Siegfried  
dc.contributor.author
Gatti, Gerardo Alberto  
dc.contributor.author
Brinkmann, Melanie M.  
dc.contributor.author
Kroger, Andrea  
dc.contributor.author
Moron, Victor Gabriel  
dc.contributor.author
Maccioni, Mariana  
dc.date.available
2018-05-28T14:50:16Z  
dc.date.issued
2016-03-15  
dc.identifier.citation
Nocera, David Andres; Roselli, Emiliano; Araya, Paula; Nuñez, Nicolas Gonzalo; Lienenklaus, Stefan; et al.; In vivo visualizing the IFN-β response required for tumor growth control in a therapeutic model of polyadenylic-polyuridylic acid administration; American Association of Immunologists; Journal of Immunology; 196; 6; 15-3-2016; 2860-2869  
dc.identifier.issn
0022-1767  
dc.identifier.uri
http://hdl.handle.net/11336/46231  
dc.description.abstract
The crucial role that endogenously produced IFN-β plays in eliciting an immune response against cancer has recently started to be elucidated. Endogenous IFN-β has an important role in immune surveillance and control of tumor development. Accordingly, the role of TLR agonists as cancer therapeutic agents is being revisited via the strategy of intra/peritumoral injection with the idea of stimulating the production of endogenous type I IFN inside the tumor. Polyadenylic-polyuridylic acid (poly A:U) is a dsRNA mimetic explored empirically in cancer immunotherapy a long time ago with little knowledge regarding its mechanisms of action. In this work, we have in vivo visualized the IFN-β required for the antitumor immune response elicited in a therapeutic model of poly A:U administration. In this study, we have identified the role of host type I IFNs, cell populations that are sources of IFN-β in the tumor microenvironment, and other host requirements for tumor control in this model. One single peritumoral dose of poly A:U was sufficient to induce IFN-β, readily visualized in vivo. IFN-β production relied mainly on the activation of the transcription factor IFN regulatory factor 3 and the molecule UNC93B1, indicating that TLR3 is required for recognizing poly A:U. CD11c(+) cells were an important, but not the only source of IFN-β. Host type I IFN signaling was absolutely required for the reduced tumor growth, prolonged mice survival, and the strong antitumor-specific immune response elicited upon poly A:U administration. These findings add new perspectives to the use of IFN-β-inducing compounds in tumor therapy.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
American Association of Immunologists  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Cancer  
dc.subject
Type I Interferon  
dc.subject
Polyadenylic-Polyuridylic Acid  
dc.subject.classification
Inmunología  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
In vivo visualizing the IFN-β response required for tumor growth control in a therapeutic model of polyadenylic-polyuridylic acid administration  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2018-05-22T21:49:11Z  
dc.journal.volume
196  
dc.journal.number
6  
dc.journal.pagination
2860-2869  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
Bethesda  
dc.description.fil
Fil: Nocera, David Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Luis. Instituto de Investigaciones en Tecnología Química. Universidad Nacional de San Luis. Facultad de Química, Bioquímica y Farmacia. Instituto de Investigaciones en Tecnología Química; Argentina  
dc.description.fil
Fil: Roselli, Emiliano. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina  
dc.description.fil
Fil: Araya, Paula. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina  
dc.description.fil
Fil: Nuñez, Nicolas Gonzalo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina  
dc.description.fil
Fil: Lienenklaus, Stefan. Helmholtz Centre for Infection Research; Alemania  
dc.description.fil
Fil: Jablonska, Jadwiga. Helmholtz Centre for Infection Research; Alemania  
dc.description.fil
Fil: Weiss, Siegfried. Helmholtz Centre for Infection Research; Alemania  
dc.description.fil
Fil: Gatti, Gerardo Alberto. Fundación Para Progreso Medicina-hospital Privado; Argentina  
dc.description.fil
Fil: Brinkmann, Melanie M.. Helmholtz Centre for Infection Research; Alemania  
dc.description.fil
Fil: Kroger, Andrea. Helmholtz Centre for Infection Research; Alemania  
dc.description.fil
Fil: Moron, Victor Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina  
dc.description.fil
Fil: Maccioni, Mariana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina  
dc.journal.title
Journal of Immunology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://www.jimmunol.org/content/196/6/2860  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.4049/jimmunol.1501044